Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

BMC Cancer

Table 6 Multivariate analysis of ABCG2 promoter methylation and its association with the overall survival of GBM patients

Variable	Haz. ratio	p-value	[95% Conf. Interval]
Sex
male	1.463	0.271	0.743	2.879
(ref. female)	1.092	0.842	0.459	2.600
(ref. female)	2.489	0.211	0.596	10.389
Age
50- < 60 years	1.745	0.317	0.586	5.195
(ref. <50 years)	1.454	0.545	0.433	4.882
(ref. <50 years)	1.552	0.760	0.092	26.033
Age
60- < 70 years	2.270	0.085	0.892	5.778
(ref. <50 years)	2.271	0.118	0.811	6.358
(ref. <50 years)	1.068	0.957	0.102	11.210
Age
≥70 years	6.112	0.001	2.087	17.903
(ref. <50 years)	9.923	0.000	2.808	35.062
(ref. <50 years)	2.774	0.376	0.290	26.572
Mean methylation level (Continuous)
	1.003	0.736	0.986	1.021
	0.998	0.836	0.977	1.019
	1.018	0.430	0.974	1.065

Continuous multivariate Cox model regression analysis of ABCG2 promoter methylation and its association with the overall survival (OS) of the analyzed patients with glioblastoma multiforme, adjusted for potential risk factors including sex and age at diagnosis and stratified on the variable therapy. Normal typed data: the entire glioblastoma cohort; Italic data: Temozolomide treated glioblastoma patients; Bold face data: Glioblastoma patients without temozolomide treatment (Haz. Ratio, Hazard Ratio; Conf. Interval, Confidence Interval).

ISSN: 1471-2407